公开(公告)号：US11279767B2

公开(公告)日：2022-03-22

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard Bourgon ,  David Fabrizio ,  Gregg Fine ,  Garrett M. Frampton ,  Priti Hegde ,  Sanjeev Mariathasan ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky

IPC: C07K16/28 ,  A61K39/395 ,  G16H20/10 ,  G16H50/30 ,  A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US11279735B2

公开(公告)日：2022-03-22

申请号：US16816969

申请日：2020-03-12

Applicant: Genentech, Inc.

Inventor： Emily J. Hanan ,  Georgette Castanedo ,  Marie Gabrielle Braun ,  Keira Garland ,  Peter Andrew Smith ,  Richard Pastor ,  Paul Gibbons ,  Yunxing Cheng ,  Guosheng Wu ,  Yuhong Fu ,  Po-Wai Yuen

IPC: C07K11/02 ,  A61K38/00

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

公开(公告)号：US20220081466A1

公开(公告)日：2022-03-17

申请号：US17332907

申请日：2021-05-27

Applicant: Genentech, Inc.

Inventor： Arick BROWN ,  Christopher J. DOWD ,  Asha Nandini-Radhamohan KEBA

IPC: C07K1/22

Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.

公开(公告)号：US20220064286A1

公开(公告)日：2022-03-03

申请号：US17526338

申请日：2021-11-15

Applicant: Genentech, Inc.

Inventor： Jane L. GROGAN ,  Robert J. JOHNSTON ,  Yan WU ,  Wei-Ching LIANG ,  Patrick LUPARDUS ,  Mahesh YADAV ,  Dhaya SESHASAYEE ,  Meredith HAZEN

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  A61K38/17

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

公开(公告)号：US11254987B2

公开(公告)日：2022-02-22

申请号：US15821407

申请日：2017-11-22

Applicant: Genentech, Inc.

Inventor： Edward Kadel ,  Marcin Kowanetz ,  Kimberly Walter

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00

Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.

公开(公告)号：US11247989B2

公开(公告)日：2022-02-15

申请号：US16198581

申请日：2018-11-21

Applicant: GENENTECH, INC. ,  CONSTELLATION PHARMACEUTICALS, INC.

Inventor： Patrick Cyr ,  Sarah Bronner ,  F. Anthony Romero ,  Steven Magnuson ,  Vickie Hsiao-Wei Tsui ,  Jeremy M. Murray ,  John Wai ,  Kwong Wah Lai ,  Fei Wang ,  Kevin X. Chen

IPC: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

公开(公告)号：US20220036548A1

公开(公告)日：2022-02-03

申请号：US17501712

申请日：2021-10-14

Applicant: GENENTECH, INC.

Inventor： Fang-Yao HU

IPC: G06T7/00 ,  G06K9/00 ,  G06K9/32 ,  G16H50/20 ,  G16H30/20 ,  G16H30/40 ,  G16H50/30 ,  G16H50/70 ,  G06N3/08 ,  A61B5/00

Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.

公开(公告)号：US11236394B2

公开(公告)日：2022-02-01

申请号：US15609473

申请日：2017-05-31

Applicant: Genentech, Inc.

Inventor： Luciana Molinero ,  Priti Hegde

IPC: C12Q1/6886

Abstract: The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.

公开(公告)号：US11225513B2

公开(公告)日：2022-01-18

申请号：US16848564

申请日：2020-04-14

Applicant: Genentech, Inc.

Inventor： Amit Mehta

IPC: C07K1/36 ,  C07K1/18 ,  C07K1/34 ,  C07K16/06

Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.

公开(公告)号：US20220008413A1

公开(公告)日：2022-01-13

申请号：US17193795

申请日：2021-03-05

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

Inventor： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother

IPC: A61K31/496

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.